Gain-of-Function Activity of Mutant p53 in Lung Cancer through Up-Regulation of Receptor Protein Tyrosine Kinase Axl

Genes and Cancer

Volumn 3, Issue 7-8, 2012, Pages 491-502

  Vaughan, Catherine A ^a   Singh, Shilpa ^a   Windle, Brad ^a,b   Yeudall, W Andrew ^a,b   Frum, Rebecca ^a   Grossman, Steven R ^a,b   Deb, Swati P ^a,b   Deb, Sumitra ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Axl; lung; mutant; p53

Indexed keywords

HISTONE ANTIBODY; PROTEIN AXL; PROTEIN P53; PROTEIN TYROSINE KINASE; RNA; UNCLASSIFIED DRUG;

ARTICLE; AXL GENE; BINDING SITE; CANCER CELL; CANCER CELL CULTURE; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LUNG CANCER; MICROARRAY ANALYSIS; MUTANT; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

EID: 84875509079     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601912462719     Document Type: Article

References (58)

1. Ahrendt SA,Hu Y,Buta M, et al.p53 mutations and survival in stage I non-small-cell lung cancer: results of a prospective study.J Natl Cancer Inst. 2003;95 (13): 961-70.
2. Miyatake K,Gemba K,Ueoka H, et al.Prognostic significance of mutant p53 protein, P-glycoprotein and glutathione S-transferase-pi in patients with unresectable non-small cell lung cancer.Anticancer Res. 2003;23 (3C): 2829-36.
3. Thompson AM,Crichton DN,Elton RA,Clay MF,Chetty U,Steel CM.Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up.Br J Cancer. 1998;77 (5): 797-800.
4. Skaug V,Ryberg D,Kure EH, et al.p53 mutations in defined structural and functional domains are related to poor clinical outcome in non-small cell lung cancer patients.Clin Cancer Res. 2000;6 (3): 1031-7.
5. Ding L,Getz G,Wheeler DA, et al.Somatic mutations affect key pathways in lung adenocarcinoma.Nature. 2008;455 (7216): 1069-75.
6. Schimmelpenning H,Eriksson ET,Zetterberg A,Auer GU.Association of immunohistochemical p53 tumor suppressor gene protein overexpression with prognosis in highly proliferative human mammary adenocarcinomas.World J Surg. 1994;18 (6): 827-32.
7. Campling BG,El-Deiry WS.Clinical implication of p53 mutation in lung cancer.Mol Biotechnol. 2003;24 (2): 141-56.
8. Oren M,Rotter V.Mutant p53 gain-of-function in cancer.Cold Spring Harb Perspect Biol. 2010;2 (2): a001107.
9. Scian MJ,Stagliano KE,Anderson MA, et al.Tumor-derived p53 mutants induce NF-kappaB2 gene expression.Mol Cell Biol. 2005;25 (22): 10097-110.
10. Scian MJ,Stagliano KE,Ellis MA, et al.Modulation of gene expression by tumor-derived p53 mutants.Cancer Res. 2004;64 (20): 7447-54.
11. Cadwell C,Zambetti GP.The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth.Gene. 2001;277 (1-2): 15-30.
12. Sigal A,Rotter V.Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.Cancer Res. 2000;60 (24): 6788-93.
13. Singer S,Ehemann V,Brauckhoff A, et al.Protumorigenic overexpression of stathmin/Op18 by gain-of-function mutation in p53 in human hepatocarcinogenesis.Hepatology. 2007;46 (3): 759-68.
14. Strano S,Dell'Orso S,Di Agostino S,Fontemaggi G,Sacchi A,Blandino G.Mutant p53: an oncogenic transcription factor.Oncogene. 2007;26 (15): 2212-9.
15. Weisz L,Damalas A,Liontos M, et al.Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells.Cancer Res. 2007;67 (6): 2396-401.
16. Lin J,Teresky AK,Levine AJ.Two critical hydrophobic amino acids in the N-terminal domain of the p53 protein are required for the gain of function phenotypes of human p53 mutants.Oncogene. 1995;10 (12): 2387-90.
17. Lanyi A,Deb D,Seymour RC,Ludes-Meyers JH,Subler MA,Deb S.'Gain of function' phenotype of tumor-derived mutant p53 requires the oligomerization/nonsequence-specific nucleic acid-binding domain.Oncogene. 1998;16 (24): 3169-76.
18. Muller PA,Vousden KH,Norman JC.p53 and its mutants in tumor cell migration and invasion.J Cell Biol. 2011;192 (2): 209-18.
19. Taylor WR,Egan SE,Mowat M,Greenberg AH,Wright JA.Evidence for synergistic interactions between ras, myc and a mutant form of p53 in cellular transformation and tumor dissemination.Oncogene. 1992;7 (7): 1383-90.
20. Shi XB,Nesslinger NJ,Deitch AD,Gumerlock PH,deVere White RW.Complex functions of mutant p53 alleles from human prostate cancer.Prostate. 2002;51 (1): 59-72.
21. Oren M,Rotter V.Mutant p53 gain-of-function in cancer.Cold Spring Harb Perspect Biol. 2010;2 (2): a001107.
22. Blandino G,Levine AJ,Oren M.Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy.Oncogene. 1999;18 (2): 477-85.
23. Lowe SW,Bodis S,McClatchey A, et al.p53 status and the efficacy of cancer therapy in vivo.Science. 1994;266 (5186): 807-10.
24. Lai SL,Perng RP,Hwang J.p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.J Biomed Sci. 2000;7 (1): 64-70.
25. Bristow RG,Peacock J,Jang A,Kim J,Hill RP,Benchimol S.Resistance to DNA-damaging agents is discordant from experimental metastatic capacity in MEF ras-transformants-expressing gain of function MTp53.Oncogene. 2003;22 (19): 2960-6.
26. Lowe SW,Ruley HE,Jacks T,Housman DE.p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.Cell. 1993;74 (6): 957-67.
27. Strano S,Blandino G.p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53.Cell Cycle. 2003;2 (4): 348-9.
28. Irwin MS,Kondo K,Marin MC,Cheng LS,Hahn WC,Kaelin WG.Chemosensitivity linked to p73 function.Cancer Cell. 2003;3 (4): 403-10.
29. Muller M,Schleithoff ES,Stremmel W,Melino G,Krammer PH,Schilling T.One, two, three: p53, p63, p73 and chemosensitivity.Drug Resist Updat. 2006;9 (6): 288-306.
30. Neilsen PM,Noll JE,Suetani RJ, et al.Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome.Oncotarget. 2011;2 (12): 1203-17.
31. Melino G.p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53.Cell Death Differ. 2011;18 (9): 1487-99.
32. Ullrich A,Schlessinger J.Signal transduction by receptors with tyrosine kinase activity.Cell. 1990;61 (2): 203-12.
33. Hafizi S,Dahlback B.Gas6 and protein S: vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily.FEBS J. 2006;273 (23): 5231-44.
34. O'Bryan JP,Frye RA,Cogswell PC, et al.axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase.Mol Cell Biol. 1991;11 (10): 5016-31.
35. Janssen JW,Schulz AS,Steenvoorden AC, et al.A novel putative tyrosine kinase receptor with oncogenic potential.Oncogene. 1991;6 (11): 2113-20.
36. Li Y,Ye X,Tan C, et al.Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis.Oncogene. 2009;28 (39): 3442-55.
37. Sawabu T,Seno H,Kawashima T, et al.Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway.Mol Carcinog. 2007;46 (2): 155-64.
38. Rochlitz C,Lohri A,Bacchi M, et al.Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK).Leukemia. 1999;13 (9): 1352-8.
39. Wimmel A,Glitz D,Kraus A,Roeder J,Schuermann M.Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion.Eur J Cancer. 2001;37 (17): 2264-74.
40. Shieh YS,Lai CY,Kao YR, et al.Expression of axl in lung adenocarcinoma and correlation with tumor progression.Neoplasia. 2005;7 (12): 1058-64.
41. Meric F,Lee WP,Sahin A,Zhang H,Kung HJ,Hung MC.Expression profile of tyrosine kinases in breast cancer.Clin Cancer Res. 2002;8 (2): 361-7.
42. Wu CW,Li AF,Chi CW, et al.Clinical significance of AXL kinase family in gastric cancer.Anticancer Res. 2002;22 (2B): 1071-8.
43. Holland SJ,Powell MJ,Franci C, et al.Multiple roles for the receptor tyrosine kinase axl in tumor formation.Cancer Res. 2005;65 (20): 9294-303.
44. Vajkoczy P,Knyazev P,Kunkel A, et al.Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival.Proc Natl Acad Sci U S A. 2006;103 (15): 5799-804.
45. Rivlin N,Brosh R,Oren M,Rotter V.Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis.Genes Cancer. 2011;2 (4): 466-74.
46. Chung BI,Malkowicz SB,Nguyen TB,Libertino JA,McGarvey TW.Expression of the proto-oncogene Axl in renal cell carcinoma.DNA Cell Biol. 2003;22 (8): 533-40.
47. Ou WB,Corson JM,Flynn DL, et al.AXL regulates mesothelioma proliferation and invasiveness.Oncogene. 2011;30 (14): 1643-52.
48. Nielsen-Preiss SM,Allen MP,Xu M, et al.Adhesion-related kinase induction of migration requires phosphatidylinositol-3-kinase and ras stimulation of rac activity in immortalized gonadotropin-releasing hormone neuronal cells.Endocrinology. 2007;148 (6): 2806-14.
49. Sainaghi PP,Castello L,Bergamasco L,Galletti M,Bellosta P,Avanzi GC.Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor.J Cell Physiol. 2005;204 (1): 36-44.
50. Scian MJ,Frum R,Deb SP,Deb S.Transactivation and transrepression studies with p53.Methods Mol Biol. 2003;234:93-110.
51. Martynova E,Pozzi S,Basile V, et al.Gain-of-function p53 mutants have widespread genomic locations partially overlapping with p63.Oncotarget. 2012;3 (2): 132-43.
52. Gaiddon C,Lokshin M,Ahn J,Zhang T,Prives C.A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.Mol Cell Biol. 2001;21 (5): 1874-87.
53. Wang H,Larris B,Peiris TH, et al.C/EBPbeta activates E2F-regulated genes in vivo via recruitment of the coactivator CREB-binding protein/P300.J Biol Chem. 2007;282 (34): 24679-88.
54. Mitsudomi T,Steinberg SM,Nau MM, et al.p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.Oncogene. 1992;7 (1): 171-80.
55. Scian MJ,Stagliano KE,Deb D, et al.Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes.Oncogene. 2004;23 (25): 4430-43.
56. Sjogren S,Inganas M,Norberg T, et al.The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.J Natl Cancer Inst. 1996;88 (3-4): 173-82.
57. Vaughan CA,Singh S,Windle B, et al.p53 mutants induce transcription of NF-kappaB2 in H1299 cells through CBP and STAT binding on the NF-kappaB2 promoter and gain of function activity.Arch Biochem Biophys. 2012;518 (1): 79-88.
58. Wang D,Baldwin AS.Activation of nuclear factor-kappaB-dependent transcription by tumor necrosis factor-alpha is mediated through phosphorylation of RelA/p65 on serine 529.J Biol Chem. 1998;273 (45): 29411-6.